WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BCAB

Based on 6 analysts offering 12 month price targets for Bioatla Inc.
Min Forecast
$8.00+130.55%
Avg Forecast
$15.67+351.5%
Max Forecast
$25.00+620.46%

Should I buy or sell BCAB stock?

Based on 6 analysts offering ratings for Bioatla Inc.
Strong Buy
Strong Buy
3 analysts 50%
Buy
2 analysts 33.33%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCAB stock forecasts and price targets.

BCAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
JMP Securities
Top 19%
82
BuyReiterates$12.00+245.82%2023-05-15
HC Wainwright & Co.
Bottom 13%
13
BuyReiterates$17.00+389.91%2023-05-15
EF Hutton
Bottom 4%
4
Strong BuyReiterates$25.00+620.46%2023-05-12
JP Morgan
Bottom 14%
14
Strong BuyMaintains$19.00+447.55%2023-04-03
BTIG
Bottom 5%
5
Strong BuyMaintains$13.00+274.64%2023-03-28
Credit Suisse
Bottom 4%
4
HoldReiterates$8.00+130.55%2023-03-24

1 of 1

Forecast return on equity

Is BCAB forecast to generate an efficient return?
Company
N/A
Industry
0.1%
Market
71.96%

Forecast return on assets

Is BCAB forecast to generate an efficient return on assets?
Company
N/A
Industry
0.12%

BCAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAB$3.47$15.67+351.50%Strong Buy
MREO$1.06$5.00+371.70%Buy
LBPH$7.19$16.40+128.09%Strong Buy
PBYI$3.55$8.00+125.35%Buy
CCCC$3.39$9.50+180.24%Hold
View Top Biotech Stocks

Bioatla Stock Forecast FAQ

Is Bioatla Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BCAB) stock is to Strong Buy BCAB stock.

Out of 6 analysts, 3 (50%) are recommending BCAB as a Strong Buy, 2 (33.33%) are recommending BCAB as a Buy, 1 (16.67%) are recommending BCAB as a Hold, 0 (0%) are recommending BCAB as a Sell, and 0 (0%) are recommending BCAB as a Strong Sell.

If you're new to stock investing, here's how to buy Bioatla stock.

What is BCAB's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: BCAB) forecast ROE is N/A, which is considered weak.

What is BCAB's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BCAB price target, the average BCAB price target is $15.67, with the highest BCAB stock price forecast at $25.00 and the lowest BCAB stock price forecast at $8.00.

On average, Wall Street analysts predict that Bioatla's share price could reach $15.67 by May 15, 2024. The average Bioatla stock price prediction forecasts a potential upside of 351.5% from the current BCAB share price of $3.47.

What is BCAB's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: BCAB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.